A patient with C7 AIS B SCI has severe extensor spasticity in both legs that prevents seated transfers and does not respond to stretching, standing programs, or oral medications. Which intervention should the therapist discuss with the medical team as a next-level option?

A patient with C7 AIS B SCI has severe extensor spasticity in both legs that prevents seated transfers and does not respond to stretching, standing programs, or oral medications. Which intervention should the therapist discuss with the medical team as a next-level option?

• A. Increasing the frequency of passive ROM to 6 times per day
• B. Ordering a firmer wheelchair cushion to resist the extensor pattern
• C. Intrathecal baclofen pump or botulinum toxin injections
• D. Discontinuing all therapy and allowing the spasticity to self-resolve

Answer: (C)

When spasticity is severe, function-limiting, and unresponsive to stretching, standing programs, and oral medications, the next step is to consider advanced pharmacologic interventions delivered in a way that targets the spinal level or specific muscles. An intrathecal baclofen pump delivers baclofen directly into the spinal fluid, producing a powerful reduction in overall spasticity with lower systemic side effects. This can make seated transfers, range of motion work, and therapy sessions more feasible. Botulinum toxin injections offer targeted reduction of tone in specific muscle groups that contribute most to the functional problems, allowing more effective positioning, transfers, and stretching. Together, these options are discussed with the medical team because they require specialist evaluation, potential procedures, and ongoing management, but they address the root challenge here: disabling extensor spasticity that isn’t helped by noninvasive measures. Increasing passive range-of-motion frequency and using a firmer wheelchair cushion may help with comfort or seating ergonomics, but they won’t meaningfully reduce the underlying spasticity to enable the necessary functional changes. Discontinuing therapy and waiting for spontaneous resolution isn’t appropriate when the spasticity is seriously limiting function and quality of life.

When spasticity is severe, function-limiting, and unresponsive to stretching, standing programs, and oral medications, the next step is to consider advanced pharmacologic interventions delivered in a way that targets the spinal level or specific muscles. An intrathecal baclofen pump delivers baclofen directly into the spinal fluid, producing a powerful reduction in overall spasticity with lower systemic side effects. This can make seated transfers, range of motion work, and therapy sessions more feasible. Botulinum toxin injections offer targeted reduction of tone in specific muscle groups that contribute most to the functional problems, allowing more effective positioning, transfers, and stretching. Together, these options are discussed with the medical team because they require specialist evaluation, potential procedures, and ongoing management, but they address the root challenge here: disabling extensor spasticity that isn’t helped by noninvasive measures.

Increasing passive range-of-motion frequency and using a firmer wheelchair cushion may help with comfort or seating ergonomics, but they won’t meaningfully reduce the underlying spasticity to enable the necessary functional changes. Discontinuing therapy and waiting for spontaneous resolution isn’t appropriate when the spasticity is seriously limiting function and quality of life.